Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mia Hedman"'
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:101-109
Background In adults, pravastatin reduces the development and progression of transplant vasculopathy, the main long-term risk after cardiac transplantation. The pharmacokinetics of pravastatin is not known in children taking calcineurin inhibitors. O
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd69b292e9028b32a36fbc09925ed603
https://doi.org/10.1016/j.clpt.2003.09.011
https://doi.org/10.1016/j.clpt.2003.09.011
Publikováno v:
Clinical Pharmacology & Therapeutics. 74:178-185
Background Pravastatin is a widely used statin in adults, but its pharmacokinetics in children is not known. Our aim was to determine the single-dose pharmacokinetics and the lipid-lowering effect and safety of short-term administration of pravastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e53bae5544bb2d8602cbf73c458f9be
https://doi.org/10.1016/s0009-9236(03)00153-x
https://doi.org/10.1016/s0009-9236(03)00153-x
Autor:
Eero Jokinen, Mia Hedman, Jouko Sundvall, Mikko Syvänne, Marjatta Antikainen, Christer Holmberg, Matti Jauhiainen, Raija Pahlman, Christian Ehnholm
Publikováno v:
Pediatric transplantation. 11(5)
The levels and protein/lipid compositions of major lipoprotein particles of 19 pediatric cardiac transplant recipients (4–18 yr of age) were studied in this prospective, open clinical follow-up study before and at one yr of pravastatin therapy (10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5a9ce67fb573411d5fad3665660d307
https://pubmed.ncbi.nlm.nih.gov/17631010
https://pubmed.ncbi.nlm.nih.gov/17631010
Autor:
Michel Eichelbaum, Kari T. Kivistö, Mia Hedman, Mikko Niemi, Mikko Neuvonen, Pertti J. Neuvonen, Marjatta Antikainen, Christer Holmberg
Our aim was to investigate associations between the single nucleotide polymorphisms (SNPs) in the SLCO1B1 (encoding OATP1B1) and ABCB1 (encoding P-glycoprotein) genes with the pharmacokinetics and efficacy of pravastatin in children with heterozygous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44fdc37f6438c21ecca2ba7797484742
https://europepmc.org/articles/PMC1885108/
https://europepmc.org/articles/PMC1885108/
Publikováno v:
The Journal of pediatrics. 148(2)
To assess causes for insufficient cholesterol-lowering response to pravastatin and plant stanol esters in children with heterozygous familial hypercholesterolemia (HeFH).Nine of 16 children with HeFH who had not reached normocholesterolemia (or =194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::883beff6f52a9195895c0afe39c6c204
https://pubmed.ncbi.nlm.nih.gov/16492436
https://pubmed.ncbi.nlm.nih.gov/16492436
Autor:
Tiina Matikainen, Mia Hedman, Matti Nuutinen, Marjatta Antikainen, Anna Föhr, Marjatta Lappi, Saila Piippo
Publikováno v:
The Journal of clinical endocrinology and metabolism. 90(4)
Heterozygous familial hypercholesterolemia (HeFH) is associated with elevated cholesterol levels and early-onset atherosclerosis. We assessed the efficacy and safety for up to 2 yr of pravastatin treatment in 19 girls and 11 boys (age range, 4.1-18.5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a03f3da0f9af26b5583a483a9e47712e
https://pubmed.ncbi.nlm.nih.gov/15657370
https://pubmed.ncbi.nlm.nih.gov/15657370